Modalis Therapeutics Corporation (JP:4883)
:4883
Want to see JP:4883 full AI Analyst Report?
4883 Stock Chart & Stats
¥56.00
-¥3.00(-2.91%)
At close: 4:00 PM EST
¥56.00
-¥3.00(-2.91%)
Day’s Range― - ―
52-Week Range¥52.00 - ¥119.00
Previous CloseN/A
Volume5.80M
Average Volume (3M)719.68K
Market Cap
¥6.15B
Enterprise Value¥2.99B
Total Cash (Recent Filing)¥3.26B
Total Debt (Recent Filing)¥0.00
Price to Earnings (P/E)―
Beta0.03
Next Earnings
May 14, 2026EPS EstimateN/A
Next Dividend Ex-DateN/A
Dividend YieldN/A
Share Statistics
EPS (TTM)-24.01
Shares Outstanding96,134,094
10 Day Avg. Volume617,120
30 Day Avg. Volume719,680
Financial Highlights & Ratios
PEG Ratio0.81
Price to Book (P/B)1.55
Price to Sales (P/S)0.00
P/FCF Ratio-2.04
Enterprise Value/Market CapN/A
Enterprise Value/RevenueN/A
Enterprise Value/Gross ProfitN/A
Enterprise Value/EbitdaN/A
Forecast
1Y Price TargetN/A
Price Target UpsideN/A
Rating ConsensusN/A
Number of Analyst Covering0
EPS Forecast (FY)-22.2
Revenue Forecast (FY)¥800.00M
Bulls Say, Bears Say
Bulls Say
Conservative Balance Sheet LeverageZero reported debt in 2024–2025 materially reduces fixed financing costs and bankruptcy risk, giving management durable optionality to fund R&D via equity or partnerships. Low leverage preserves strategic flexibility during lengthy drug development cycles.
Platform Focus On Gene Expression–modulating TherapiesA clear platform orientation toward gene expression modulation aligns with secular growth in genetic-disease therapeutics and can create high technical barriers. If clinical advances occur, platform assets support multiple programs and durable licensing/partnership opportunities.
Lean Operating FootprintA small headcount indicates a lean cost structure and focused R&D operations, which can extend runway per financing round and improve capital efficiency. For a pre-revenue biotech, a compact team supports nimble program prioritization and lower fixed overhead over months.
Bears Say
Minimal-to-zero RevenueSustained absence of product revenue means the business remains pre-commercial and must rely on successful R&D or external financing to reach sustainable operations. This elevates execution risk and prevents internal funding of development or commercialization over the medium term.
Persistent Cash Burn And Negative Operating Cash FlowOngoing negative operating and free cash flow indicate structural funding needs and increase liquidity risk. Continued cash burn without revenue amplifies dependence on external capital, raising dilution and potentially constraining program advancement if markets tighten.
Eroding Equity Base From Cumulative LossesMeaningful erosion of shareholders' equity over several years reduces the company's balance-sheet cushion and financial flexibility. This trend increases the likelihood of future dilutive financing, weakens negotiating leverage in partnerships, and raises long-term funding cost.
Modalis Therapeutics Corporation News
4883 FAQ
What was Modalis Therapeutics Corporation’s price range in the past 12 months?
Modalis Therapeutics Corporation lowest stock price was ¥52.00 and its highest was ¥119.00 in the past 12 months.
What is Modalis Therapeutics Corporation’s market cap?
Modalis Therapeutics Corporation’s market cap is ¥6.15B.
When is Modalis Therapeutics Corporation’s upcoming earnings report date?
Modalis Therapeutics Corporation’s upcoming earnings report date is May 14, 2026 which is in 6 days.
How were Modalis Therapeutics Corporation’s earnings last quarter?
Modalis Therapeutics Corporation released its earnings results on Feb 12, 2026. The company reported -¥3.95 earnings per share for the quarter, missing the consensus estimate of N/A by -¥3.95.
Is Modalis Therapeutics Corporation overvalued?
According to Wall Street analysts Modalis Therapeutics Corporation’s price is currently Overvalued.
Does Modalis Therapeutics Corporation pay dividends?
Modalis Therapeutics Corporation does not currently pay dividends.
What is Modalis Therapeutics Corporation’s EPS estimate?
Modalis Therapeutics Corporation’s EPS estimate for its next earnings report is not yet available.
How many shares outstanding does Modalis Therapeutics Corporation have?
Modalis Therapeutics Corporation has 96,134,094 shares outstanding.
What happened to Modalis Therapeutics Corporation’s price movement after its last earnings report?
Modalis Therapeutics Corporation reported an EPS of -¥3.95 in its last earnings report, missing expectations of N/A. Following the earnings report the stock price went up 1.724%.
Which hedge fund is a major shareholder of Modalis Therapeutics Corporation?
Currently, no hedge funds are holding shares in JP:4883
What is the TipRanks Smart Score and how is it calculated?
Smart Score combines eight research factors - such as analyst recommendations, hedge fund trends, and technical indicators - to measure a stock’s outlook. These signals are unified into a single score that reflects bullish or bearish momentum. See detailed methodology
Company Description
Modalis Therapeutics Corporation
Modalis Therapeutics Corporation engages in the research and development of therapeutics to treat patients with serious genetic disorders. It is developing therapies for genetic diseases using its proprietary CRISPR-GNDM technology that enables to control gene expressions through modulating the switch (epigenetics of a specific locus. The company has a. joint research agreement with JCR Pharmaceuticals Co., Ltd. to evaluate the drug delivery technology of the gene therapy to the central nervous system (CNS) assuming CNS diseases as a target. The company was formerly known as EdiGENE Corporation and changed its name to Modalis Therapeutics Corporation in August 2019. Modalis Therapeutics Corporation was founded in 2016 and is headquartered in Tokyo, Japan.
Technical Analysis
Solasia Pharma KK
―
Nippon Chemiphar Co., Ltd.
―
Taiko Pharmaceutical Co., Ltd.
―
Symbio Pharmaceuticals Limited
―
Cyfuse Biomedical K.K.
―